<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03560908</url>
  </required_header>
  <id_info>
    <org_study_id>IHBDH-IIT2018004</org_study_id>
    <nct_id>NCT03560908</nct_id>
  </id_info>
  <brief_title>Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation</brief_title>
  <official_title>Dasatinib Combined With Multi-agents Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Hematology &amp; Blood Diseases Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Hematology &amp; Blood Diseases Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this multi-center, open-label, no control,prospective clinical trial, a total of 30
      relapsed acute myeloid leukemia with t(8;21) translocation and KIT D816 mutation patients
      will be enrolled. Dasatinib 70 mg twice a day will be administrated for two weeks from day 1
      of re-induction chemotherapy. The purpose of current study is to determine the clinical
      efficacy and tolerability of combination therapy of dasatinib with multi-agent chemotherapy
      in relapsed acute myeloid leukemia with t(8;21) translocation and KIT D816 mutation.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No enough eligable participants enrolled
  </why_stopped>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>composite complete remission (CR) rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>confirmed rate of complete remission (CR) plus complete remission with incomplete blood count(CRi)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mortality during induction chemotherapy</measure>
    <time_frame>30 days</time_frame>
    <description>all deaths from start of chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>post relapsed overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>2 years overall survival from the date of relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>5 years overall survival from the date of diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>post relapsed disease free survival</measure>
    <time_frame>2 years</time_frame>
    <description>2 years disease free survival from the date of new complete remission</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Relapsed AML</condition>
  <condition>T(8;21)</condition>
  <condition>C-KIT Mutation</condition>
  <arm_group>
    <arm_group_label>Dasatinib plus chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dasatinib combined with chemotherapy for relapsed t(8;21) AML with D816 mutation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>Dasatinib 70mg twice a day will be administered orally for 2 weeks along with re-induction chemotherapy from day 1 of chemotherapy. Recommended re-induction regimens include (1)FLAG: Fludarabine 30mg/m2/d,d1-5;cytarabine 1g-2g/m2/d,d1-5;±G-CSF;(2)IA/DA:idarubicin 8-12mg/m2/d,d1-3 or daunorubicin 45-60mg/m2/d，d1-3;cytarabine 100-200mg/m2/d，d1-7;(3)CAG:Aclarubicin 20mg/d,d1-4；cytarabine 15mg/m2/Q12h,d1-14; ±G-CSF.The chemotherapy regimen is not limited to recommended regimens. Patients will be recommended to receive allogeneic hematopoietic stem cell transplantation (HSCT) once complete remission is achieved. Otherwise, they will continue the consolidation chemotherapy.</description>
    <arm_group_label>Dasatinib plus chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. T(8;21)acute myeloid leukemia patients with KIT D816 mutation diagnosed by bone marrow
             morphology, immunology, molecular genetics. The diagnosis and classification are
             according to WHO 2016 criteria.

          2. Conform to relapsed diagnosis.Only morphological relapsed cases will be
             enrolled.Molecular relapsed and isolated extramedullary relapsed cases are not
             eligible.

          3. Age is not limited. Both male and female are eligible.

          4. Eastern Cooperative Oncology Group performance status (ECOG-PS):0-2 point.

          5. Informed consent form must be signed by patients themselves before enrolled for
             patients aged 18 years or older. Informed consent form must be signed by the legal
             guardian for patients younger than 18 years.

        Exclusion Criteria:

          1. Patients with other blood diseases at the same time (such as haemophilia, primary
             myelofibrosis and so on) are not considered suitable.

          2. Isolated extramedullary relapsed leukemia.

          3. With other malignant tumors accompanied with AML and needed treatment. 4 .Patients who
             are unsuitable for the trial considered by investigators.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianxiang Wang, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Hematology &amp; Blood Diseases Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HBDH</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 1, 2018</study_first_submitted>
  <study_first_submitted_qc>June 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2018</study_first_posted>
  <last_update_submitted>March 19, 2020</last_update_submitted>
  <last_update_submitted_qc>March 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute of Hematology &amp; Blood Diseases Hospital</investigator_affiliation>
    <investigator_full_name>wang, jianxiang</investigator_full_name>
    <investigator_title>Vice President of Institute</investigator_title>
  </responsible_party>
  <keyword>leukemia,myeloid, acute</keyword>
  <keyword>relapse</keyword>
  <keyword>mutation</keyword>
  <keyword>KIT</keyword>
  <keyword>dasatinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

